Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CMS Coverage Appeals Proposed Rule Needs Substantial Revision – AdvaMed

This article was originally published in The Gray Sheet

Executive Summary

The Centers for Medicare & Medicaid Services should refrain from adopting its Aug. 22 proposed rule on review of national and local coverage determinations, AdvaMed contends in Oct. 21 comments to the agency

You may also be interested in...



Medicare Coverage Appeals Final Rule Expands Beneficiary Rights – CMS

Coverage decision appeals by individual Medicare beneficiaries may have "implications" for future coverage of a device for all beneficiaries under CMS' final appeals rule, the agency maintains

Medicare Coverage Appeals Final Rule Expands Beneficiary Rights – CMS

Coverage decision appeals by individual Medicare beneficiaries may have "implications" for future coverage of a device for all beneficiaries under CMS' final appeals rule, the agency maintains

Medicare Appeals Rule Expedited By Visudyne Settlement; MCAC To Convene

CMS' Medicare Coverage Advisory Committee will review initial data from QLT, Inc.'s Phase III trial investigating Visudyne (verteporfin) ocular photodynamic therapy in age-related macular degeneration patients with occult lesions

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT017354

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel